1. National Cancer Institute: Surveillance Epidemiology and End Results. 2008, [
http://www.seer.cancer.gov
]
2. Blackwell K, Kaplan H, Franco S, Marcom P: A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology Annual ASCO meeting. 2004
3. Gomez H, Chavez M, Doval D: Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer. Breast Cancer Research and Treatment. 2005, suppl 1(S63):
4. Kaufman B, Trudeau M, Johnston S, Awada A: Clinical activity of lapatinib monotherapy in patients with HER2+ relapsed/refractory inflammatory breast cancer (IBC): Final results of the expanded HER2+ cohort in EGF103009. journal of Clinical Oncology annual ASCO meeting. 2008
5. Geyer C, Forster J, Lindquist D, Chan S: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New England Journal of Medicine. 2006, 355: 2733-43. 10.1056/NEJMoa064320.